Jiangsu HengRui Medicine Co., Ltd.: Carcinoma, Hepatocellular trials
The registry lists 10 Carcinoma, Hepatocellular studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 1 1Phase 2 4Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingNCT07691762Phase 3
- Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT05444088Phase 1/2
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)CompletedNCT03463876Phase 2Results posted
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Phase 2Results posted
- Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)CompletedNCT02329860Phase 3Results posted
- A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular CarcinomaActive, not recruitingNCT05320692Phase 3
- A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT04985136Phase 3
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Phase 3
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.Status unknownNCT03605706Phase 3
- A Study of Apatinib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT01192971Phase 2